Article
Response to the Canadian Agency for Drugs and Technologies in Health and Institut national d'excellence en santé et en services sociaux decision regarding nusinersen for Spinal Muscular Atrophy.
The Canadian Journal of Neurological Sciences / Le Journal Canadien des Sciences Neurologiques
Document Type
Article
Publication Date
9-1-2018
URL with Digital Object Identifier
https://doi.org/10.1017/cjn.2018.59
Disciplines
Citation Information
Craig Campbell, Kathy Selby, Hugh McMillan, Jiri Vajsar, et al.. "Response to the Canadian Agency for Drugs and Technologies in Health and Institut national d'excellence en santé et en services sociaux decision regarding nusinersen for Spinal Muscular Atrophy." The Canadian Journal of Neurological Sciences / Le Journal Canadien des Sciences Neurologiques Vol. 45 Iss. 5 (2018) p. 516 - 517 Available at: http://works.bepress.com/craig-campbell/30/
Article available at The Canadian Journal of Neurological Sciences / Le Journal Canadien des Sciences Neurologiques
https://doi.org/10.1017/cjn.2018.59
All authors contributed equally to the creation of this statement.
© 2018 The Canadian Journal of Neurological Sciences Inc.